450 related articles for article (PubMed ID: 37457288)
1. Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer.
Geng P; Chi Y; Yuan Y; Yang M; Zhao X; Liu Z; Liu G; Liu Y; Zhu L; Wang S
Front Cell Dev Biol; 2023; 11():1158539. PubMed ID: 37457288
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy.
Zaib T; Cheng K; Liu T; Mei R; Liu Q; Zhou X; He L; Rashid H; Xie Q; Khan H; Xu Y; Sun P; Wu J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768478
[TBL] [Abstract][Full Text] [Related]
3. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
4. CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil.
Nasiri F; Kazemi M; Mirarefin SMJ; Mahboubi Kancha M; Ahmadi Najafabadi M; Salem F; Dashti Shokoohi S; Evazi Bakhshi S; Safarzadeh Kozani P; Safarzadeh Kozani P
Front Immunol; 2022; 13():1018786. PubMed ID: 36483567
[TBL] [Abstract][Full Text] [Related]
5. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.
Dees S; Ganesan R; Singh S; Grewal IS
Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511
[TBL] [Abstract][Full Text] [Related]
6. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
7. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
9. EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both
Xia L; Zheng ZZ; Liu JY; Chen YJ; Ding JC; Xia NS; Luo WX; Liu W
Clin Transl Immunology; 2020 May; 9(5):e01135. PubMed ID: 32373345
[TBL] [Abstract][Full Text] [Related]
10. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
Front Immunol; 2020; 11():573823. PubMed ID: 33072116
[TBL] [Abstract][Full Text] [Related]
11. Progress and challenges of immunotherapy in triple-negative breast cancer.
Zhu Y; Zhu X; Tang C; Guan X; Zhang W
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell therapy for triple-negative breast cancer: Where we are.
Xie Y; Hu Y; Zhou N; Yao C; Wu L; Liu L; Chen F
Cancer Lett; 2020 Oct; 491():121-131. PubMed ID: 32795486
[TBL] [Abstract][Full Text] [Related]
13. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress.
Corti C; Venetis K; Sajjadi E; Zattoni L; Curigliano G; Fusco N
Expert Opin Investig Drugs; 2022 Jun; 31(6):593-605. PubMed ID: 35311430
[TBL] [Abstract][Full Text] [Related]
14. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
15. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.
Wang X; Qi Y; Kong X; Zhai J; Li Y; Song Y; Wang J; Feng X; Fang Y
Cancer Lett; 2019 Feb; 442():409-428. PubMed ID: 30419345
[TBL] [Abstract][Full Text] [Related]
16. Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling.
Zhou M; Chen M; Shi B; Di S; Sun R; Jiang H; Li Z
Mol Ther; 2022 Nov; 30(11):3379-3393. PubMed ID: 35927951
[TBL] [Abstract][Full Text] [Related]
17. EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC.
Liu Y; Zhou Y; Huang KH; Li Y; Fang X; An L; Wang F; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
Aging (Albany NY); 2019 Dec; 11(23):11054-11072. PubMed ID: 31804974
[TBL] [Abstract][Full Text] [Related]
18. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook.
Obidiro O; Battogtokh G; Akala EO
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37513983
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in antibody-based therapeutics for triple-negative breast cancer.
Ning WJ; Liu X; Zeng HY; An ZQ; Luo WX; Xia NS
Expert Opin Drug Deliv; 2022 Jul; 19(7):815-832. PubMed ID: 35738312
[TBL] [Abstract][Full Text] [Related]
20. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.
Hu Z
Sci Rep; 2020 Feb; 10(1):2815. PubMed ID: 32071339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
